Safety is a major cause of attrition in drug discovery and development 1,2 and is, thus, a key consideration when making decisions at the major transition points in the drug pipeline (Box 1).
In the contemporary context of an acute need for sustainability and swift response to imminent crises such as global warming, pandemics and economic system disruptions, the focus on responsible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results